US Congress passes BARDA legislation

18 December 2006

Early on December 9 - a Saturday - the US House of Representatives passed S 3678, the Pandemic and All-Hazards Preparedness Act.

Welcoming the move, Biotechnology Industry Organization president Jim Greenwood said: "this bill includes critical Biomedical Advanced Research and Development Authority (BARDA) provisions and provisions to reauthorize bioterrorism grants and is a necessary step toward improving America's defenses against bioterrorism and pandemic diseases." This legislation recognizes that there remains a barrier to effective countermeasure product development, and authorizes the BARDA within the Department of Health and Human Services. Through this, contracts and grants for advanced R&D will be made to firms working on products to protect US citizens.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight